Article Commentary: Streamlining the Clinical Research Enterprise

U.S. Department of Health and Human Services, Federal Policy for the Protection of Human Subjects: Notices and Rules, 56 Fed Reg 28,002–28,032 (Rev. Nov. 13, 2001), including 45 CFR pt 46.

National Bioethics Advisory Commission. Ethical and Policy Issues in Research Involving Human Participants: Volume I. Report and Recommendations of the National Bioethics Advisory Commission, Bethesda, MD, August 2001. Bethesda, MD: National Bioethics Advisory Commission, 2001 (ISBN 1-931022-16-X). Available at: http://www.georgetown.edu/research/nrcbl/nbac/human/overvol1.html. Accessed July 11, 2002.

Office for Human Research Protections (OHPR), U.S. Department of Health and Human Services. OHRP/OPRR compliance activities: Determination letters. Available at: http://ohrp.osophs.dhhs.gov/detrm_letrs/lindex.htm. Accessed July 11, 2002.

Kalb PE , Koehler KG. Legal issues in scientific research. JAMA 2002;287:85–91.

Office of the Inspector General, U.S. Department of Health and Human Services. Institutional Review Boards: A time for reform (No. OEI-01-97-00193). Washington, DC: U.S. Department of Health and Human Services, 1998.

Lo B , Wolf LE , Berkeley A. Conflict-of-interest policies for investigators in clinical trials. N Engl J Med 2000;343:1616–1620.

Lemonick MD , Goldstein A. At your own risk: Some patients join clinical trials out of desperation, others to help medicine advance: Who is to blame if they get sick—or even die? Time 2002;159(16):46–56.

Stolberg SG. The biotech death of Jesse Gelsinger. N Y Times Mag 1999 Nov 28; 136–140, 149–150.

Steinbrook R. Protecting research subjects: The crisis at Johns Hopkins. N Engl J Med 2002;346:716–720.

Nathan DG. Careers in translational clinical research: Historical perspectives, future challenges. JAMA 2002;287:2424–2427.

Harris Interactive Poll. There are many reasons why people are reluctant to participate in clinical trials. Available at: http://www.harrisinteractive.com/news/newsletters/healthnews/HI_HealthCareNews2002Vol2_Iss07.pdf

U.S. General Accounting Office. Scientific research: Continued vigilance critical to protecting human subjects (Letter Report to the Ranking Minority Member, Hon. John Glenn, Committee on Governmental Affairs, U.S. Senate, 03/08/96, GAO/HEHS-96-72). Washington, DC: General Accounting Office, 1996.

Shalala D. Protecting research subjects: What must be done. N Engl J Med 2000;343:808–810.

Lepay D . The role of regulation in clinical trials: An FDA perspective. Presented at the meeting of the Institute of Medicine's Clinical Research Roundtable, Washington, DC, June 13, 2002. Available at: http://www4.nationalacademies.org/IOM/iomhome.nsf/18ace18eb695f74c85256691007102f5/80a297d0e5fec6ea85256be2006bdb26/$FILE/Lepay2.ppt. July 11, 2002.

National Institutes of Health, U.S. Department of Health and Human Services. Human participant protections education for research teams (on-line tutorial). Available at: http://cme.nci.nih.gov/. Accessed July 11, 2002.

Gallin J. Conducting clinical research: Suggestions for improvement. Presented at the meeting of the Institute of Medicine's Clinical Research Roundtable, Washington, DC, June 13, 2002.